Quest Diagnostics (DGX), Why Is This Latest Update Drawing Attention?
Quest Diagnostics (DGX) drew fresh attention after its board declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026, to shareholders of record on October 6, 2026.
See our latest analysis for Quest Diagnostics.
At a share price of $236.04, Quest Diagnostics has pulled back slightly in the last week, although the 30 day share price return of 14.58% and year to date share price return of 35.82% sit alongside a 3 year total shareholder return of 89.30%, which suggests momentum has been building over both shorter and longer periods.
If this dividend announcement has you thinking about where else to find potential growth in healthcare, you can widen your search using our screener for 44 healthcare AI stocks.
After such a strong run and a fresh dividend on the table, Quest Diagnostics now asks investors to weigh how much upside is left versus the risks from here. Do the current numbers still justify new money going in?
Most Popular Narrative: 4% Undervalued
The most followed narrative on Quest Diagnostics sees fair value at about $245.87 compared with the last close of $236.04. That view leans on a detailed set of growth, margin and valuation assumptions rather than short term share price moves.
The rising importance of health data analytics and Quest's role as a "lab engine" for consumer wellness brands positions the company to benefit from new revenue streams and further monetization opportunities as healthcare becomes more data-driven, supporting long-term earnings power.
Curious what sits behind that fair value gap for Quest Diagnostics. The narrative leans heavily on steady top line expansion, firmer margins and a richer future earnings multiple. Want to see how those three levers combine into the current price target and what assumptions really have to hold for this story to play out.
Result: Fair Value of $245.87 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that fair value gap for Quest Diagnostics still depends on reimbursement policy not tightening materially and on wage and investment costs staying under control.
Find out about the key risks to this Quest Diagnostics narrative.
Next Steps
With both risks and rewards in play for Quest Diagnostics, it makes sense to review the details yourself and move quickly to shape your own view. You can start by weighing the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Quest Diagnostics?
If Quest Diagnostics has sharpened your focus, do not stop here. The next step is lining up a few more high conviction ideas before the market moves on.
- Spot potential turnaround opportunities early by reviewing 20 elite penny stocks with strong financials that pair smaller market sizes with more resilient financial profiles.
- Hunt for quality at a measured price with the 51 high quality undervalued stocks that filters for companies combining stronger cash flows and balance sheets with compressed valuations.
- Prioritise resilience and capital preservation by checking the 88 resilient stocks with low risk scores so you always have a watchlist of sturdier options ready.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com